New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 894-901

  O'Dell, Kate M ^a   Igawa, Daniel ^a   Hsin, Jerline ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Anticoagulants; Apixaban; Dabigatran; Direct thrombin inhibitors; Factor Xa inhibitors; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSPEPSIA; ELECTROCARDIOGRAPHY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; NAUSEA; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84859605332     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.019     Document Type: Article

References (26)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
2. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl 6):S546-S592.
3. Neel S. Essential warfarin knowledge. Managing Anticoagulation Patients in the Hospital 2007, 133-175. American Society of Health-System Pharmacists, Bethesda, Md. M. Gulseth (Ed.).
4. Bauer K.A. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011, 9(Suppl 1):S12-S19.
5. Mavrakanas T., Bounameaux H., Chatzizisis Y. Pharmacology and therapeutics: the potential role of new anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011, 130:46-58.
6. Pradaxa [prescribing information] 2011, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Conn.
7. Xarelto [prescribing information] 2011, Janssen Pharmaceuticals, Inc., Titusville, NJ.
8. ® (apixaban) new drug application for review for the prevention of stroke and systemic embolism in patients with atrial fibrillation [press release]; November 29, 2011 Pfizer, Accessed January 13, 2012. http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp#guid=20111129006025en&source=RSS_2011&page=3.
9. Connolly S.J., Ezekowitz M.D., Ysuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
10. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
11. Granger C.B., Alexander J.H., McMurray J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
12. Ahrens I., Lip G.Y., Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010, 104:49-60.
13. Ahrens I., Lip G.Y., Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation. Thromb Haemost 2011, 105:574-578.
14. Mega J.L. A new era for antcoagulation in atrial fibrillation. N Engl J Med 2011, 365:1052-1054.
15. Diener H.C., Connolly S.J., Ezekowitz M.D., et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163.
16. Rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation Food and Drug Administration, Accessed November 29, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270797.pdf.
17. Ghanny S., Warkentin T.E., Crowther M.A. Reversing anticoagulant therapy. Curr Drug Discov Technol 2011, Epub online 21 Oct 2011 [Epub ahead of print].
18. Hirsh J., Guyatt G., Albers G.W., et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(Suppl 6):71S-109S.
19. Ganetsky M., Babu K.M., Salhanick S.D., et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011, 7:281-287.
20. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
21. Van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
22. Van Ryn J., Ruehl D., Priepke H., et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008, 93(Suppl 1):S148. Abstract 0370.
23. Escolar Gines Evaluation of the potential action of coagulation factors concentrates in the reversal of the antithrombotic action of new oral Anticoagulants: studies ex vivo in blood samples from healthy volunteers Ministry of Health, Spain, 2011 [cited 2012 Jan 13]. NLM Identifier: NCT01478282. http://clinicaltrials.gov/ct2/show/NCT01478282.
24. Clemens A., Haertter S., Friedman J., et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation-a pharmacokinetic justification. Curr Med Res Opin 2012, 28:195-201.
25. Post-marketing surveillance on the long-term use of Pradaxa capsules in patients with nonvalvular atrial fibrillation Boehringer Ingelheim Pharmaceuticals, 2011 [cited 2012 Jan 13]. NLM Identifier: NCT01491178. http://clinicaltrials.gov/ct2/show/NCT01491178.
26. RELY-ABLE Long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge translation intervention on patient outcomes Boehringer Ingelheim Pharmaceuticals, 2008 [cited 2012 Jan 13]. NLM Identifier: NCT00808067. http://clinicaltrials.gov/ct2/show/NCT00808067.